medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Clinical validation of novel second-trimester preterm preeclampsia risk predictors combining clinical variables and serum protein biomarkers

Louise C. LAURENT, MD, PhD[1*], George R. SAADE, MD[2], Glenn R. MARKENSON, MD[3], Kent D. HEYBORNE, MD[4], Corina N. SCHOEN, MD[5], Jason K. BAXTER, MD[6], Sherri A. LONGO, MD[7], Leonardo M. PEREIRA, MD[8], Emily J. SU, MD[9], Matthew K. HOFFMAN, MD[10], Garrett K. LAM, MD[11], Angela C. FOX, MS[12], Ashoka D. POLPITIYA, D Sc[12], Md. Bahadur BADSHA, PhD[12], Tracey C. FLEISCHER, PhD[12], Thomas J. GARITE, MD[12], J. Jay BONIFACE, PhD[12], Paul E. KEARNEY, PhD[12]

[1]Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, La Jolla, CA

[2]Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA

[3]Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston, MA

[4]Department of Obstetrics and Gynecology, Denver Health and Hospital Authority, Denver, CO, and Department of Obstetrics and Gynecology, University of Colorado Denver, Aurora, CO

[5]Department of Obstetrics and Gynecology, University of Massachusetts-Baystate, Springfield, MA

[6]Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA

[7]Department of Obstetrics and Gynecology, Ochsner Health, New Orleans, LA

[8]Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR

[9]Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO

[10]Department of Obstetrics and Gynecology, ChristianaCare Health System, Wilmington DE

[11]Regional Obstetrical Consultants, Chattanooga, TN; Department of Obstetrics & Gynecology, University of Tennessee Health Science Center and College of Medicine, Chattanooga, TN

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

[12]Sera Prognostics, Inc., Salt Lake City, UT

***Corresponding Author**

Louise C. LAURENT, MD, PhD

Professor

Co-Chair, Center for OB/GYN Research Innovation

Department of Obstetrics, Gynecology, and Reproductive Sciences

Division of Maternal Fetal Medicine

The Sanford Consortium for Regenerative Medicine

University of California, San Diego

2880 Torrey Pines Scenic Dr.

La Jolla, CA 92037-0695

Phone: 858-246-1405

FAX: 858-534-8329

llaurent@ucsd.edu

Financial support

Financial support for the study was provided by Sera Prognostics, Inc. The sponsor funded the study, generated biomarker data and discovered and blindly validated the predictors.

Short title

Proteomic biomarker risk predictors for preterm preeclampsia

Acknowledgments

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Study funding was provided by Sera Prognostics, Inc. Jennifer Logan, PhD, an employee of Sera Prognostics, Inc., contributed to the writing of this article. Babak Shahbaba, PhD (University of California Irvine), conducted independent validation hypothesis testing. The authors wish to acknowledge the following co-investigators on the original PAPR and/or TREETOP studies: Kim A. Boggess, MD (University of North Carolina School of Medicine); Dean V. Coonrod, MD (University of Arizona College of Medicine); Larry M. Cousins, MD (San Diego Perinatal Center; Rady Children's Specialists of San Diego); Amy H. Crockett, MD (University of South Carolina School of Medicine Greenville and Prisma Health-Upstate); M. Sean Esplin, MD (Intermountain Healthcare); William A. Grobman, MD, MBA (The Ohio State University Wexner Medical Center); David M. Haas, MD (Indiana University School of Medicine); Angela F. Hawk, MD (Regional Obstetrical Consultants); Jay D. Iams, MD (The Ohio State University Wexner Medical Center); Carol A. Major, MD (University of California Irvine School of Medicine); Scott A. Sullivan, MD (Medical University of South Carolina); and Sarahn M. Wheeler, MD (Duke University School of Medicine). The authors also thank the study coordinators and research personnel at the study sites, the clinical study participants, and the Sera Prognostics, Inc. research and development, clinical laboratory and clinical operations teams.

Preprint

A preprint of this manuscript has been posted at

https://www.medrxiv.org/content/10.1101/2022.12.21.22282936.

Manuscript word count: 3372

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Clinical validation of novel second-trimester preterm preeclampsia risk predictors combining clinical variables and serum protein biomarkers

Précis

Combining novel serum protein biomarkers and selected clinical variables for preterm preeclampsia prediction outperforms widely used clinical risk assessment algorithms currently recommended by practice guidelines.

Abstract

Objective

To develop and validate mid-trimester preterm preeclampsia (PE) risk predictors combining clinical factors and serum protein analytes, and to compare their performance with those of widely used clinical and risk assessment algorithms endorsed by professional societies.

Methods

This was a secondary analysis of data from two large, multicenter studies in pregnant individuals (PAPR, NCT01371019; TREETOP, NCT02787213), originally conducted to discover, verify, and validate a serum proteomic predictor of preterm birth risk. Serum protein abundances were determined by mass spectrometry. Classifier models combined one or two novel protein ratio(s) with a composite clinical variable, denoted as ClinRisk3, which included prior PE, pre-existing hypertension, or pregestational diabetes. Predictive performance was assessed for the full validation cohort and for a subset that had early gestational age (GA) dating via ultrasound. Classifier performance was compared directly to the U.S. Preventive Services Task Force (USPSTF) algorithm for identification of pregnancies that should receive low-dose aspirin (LDASA) for PE prevention.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Results

Nine of nine prespecified classifier models were validated for risk of preterm PE with delivery <37 weeks' gestation. Areas under the receiver operating characteristic curve ranged from 0.72-0.78 in the full validation cohort, compared to 0.68 for both ClinRisk3 alone and for the USPSTF algorithm. In the early GA dating subcohort, an exemplar predictor, ClinRisk3 + inhibin subunit beta C chain/sex hormone binding globulin (ClinRisk3+INHBC/SHBG) showed a markedly lower screen positive rate (11.1% vs 43.3%) and higher positive predictive value (13.0% vs 5.0%) and odds ratio (9.93 vs 5.24) than USPSTF. Its performance was similar in nulliparas and all parities.

Conclusion

Nine preterm PE risk predictors were identified, validated in an independent cohort, and shown to be more predictive than the USPSTF-endorsed algorithm. Our results indicate that a single blood test performed in the first half of pregnancy can be used for personalized PE risk assessment, particularly for pregnancies with minimal or no identified clinical risk factors, including nulliparas. Results can be used to guide personalized pregnancy management, including but not restricted to LDASA for PE prophylaxis, and serve as a basis for developing new prevention strategies.

Funding Source

Sera Prognostics, Inc.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Introduction

Preeclampsia (PE) occurs in ~5-7% of pregnancies[1] and is implicated in 14% of maternal[2] and 10-25% of perinatal[3] deaths. It is associated with approximately one-quarter of all preterm births (PTBs) and 50% of medically indicated PTBs.[4] The only cure for PE is delivery, with other therapies focused on preventing or delaying onset (low-dose aspirin [LDASA]),[5] preventing end-organ damage (antihypertensive medications to prevent strokes[6] and magnesium sulfate to prevent seizures),[7] and reducing neonatal complications of prematurity (antenatal steroids).[7] Because PE-associated perinatal morbidity and mortality and healthcare costs correlate with prematurity,[8,9] accurate prediction of preterm PE (gestational age [GA] at delivery [GAD] <37 weeks) is of greater clinical and economic value than prediction of term PE.

Until recently, PE prediction relied largely on clinical risk factors, including: PE in a previous pregnancy; high body mass index (BMI); maternal chronic hypertension, diabetes, renal disease, and autoimmune conditions; and obstetric characteristics such as multiple gestation and use of assisted reproductive technologies.[7] PE and gestational hypertension in a previous pregnancy are among the most predictive and commonly used risk factors but are irrelevant in nulliparous pregnancies.

Numerous PE-associated molecular biomarkers have been reported,[10-13] including soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF). In patients with clinically suspected PE, sFlt-1 and PlGF measurement enables earlier diagnosis and/or modestly decreases adverse maternal outcomes.[14,15] but do not adequately predict PE risk in asymptomatic pregnancies. Strategies incorporating combinations of serum analytes, patient history, blood pressure, and uterine artery pulsatility index accurately predict PE risk in asymptomatic pregnancies but are not widely used, as they require sophisticated equipment with trained sonographers along with molecular analyses. [16,17] Also, sFlt-1 and PlGF clinical studies have focused on late-onset PE; included only cases conforming to classical definitions; or grouped PE cases across all GAs and/or severities together. Since PE is highly

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

heterogeneous,[18,19] biomarker studies should at minimum assess performance for early-onset and late-onset cases separately.[8,20,21]

There is an urgent need for an accurate, safe, and practical predictor for preterm PE, particularly for nulliparas. A predictor with good AUC (>0.70), sensitivity (>50%), and PPV (>5%) at a reasonably low screen positive rate (SPR) (<15%) would markedly improve identification of high-risk pregnancies for LDASA prophylaxis, increased surveillance, and research studies compared to current clinical paradigms, while a high negative predictive value (NPV; >99%) would enable low-risk patients to safely forgo or discontinue unnecessary interventions. This study aimed to develop and validate a mid-trimester predictor comprising molecular biomarkers and relevant clinical factors across demographically, geographically, and temporally diverse populations, comparing predictive performance to that of currently used risk assessment paradigms.

Methods

Biomarker development was based on U.S. National Academy of Medicine guidelines.[22] This was a secondary analysis, using data from two large, multicenter U.S. cohort studies, conducted to discover, verify, and validate risk predictors for preterm PE. The Proteomic Assessment of Preterm Risk (PAPR, NCT01371019)[23] and the Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor (TREETOP, NCT02787213)[24] studies were prospective, observational studies conducted to develop a maternal serum-based proteomic biomarker for PTB risk stratification. Study approvals were provided by site IRBs, and participants provided written informed consent.

PAPR and TREETOP enrolled gravidas ≥18 years of age with singleton pregnancies from $17^{0/7}$-$28^{6/7}$ or $17^{0/7}$-$21^{6/7}$ weeks' gestation, respectively, and excluded pregnancies with planned delivery <$37^{0/7}$ weeks' gestation, major anomalies or chromosomal disorders, or planned cervical cerclage. GA was determined according to ACOG criteria[25,26]. In TREETOP, progesterone use after $13^{6/7}$ weeks' gestation

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

was an exclusion criterion. Demographic, medical and pregnancy history, medication, and post-delivery maternal and infant outcome information was collected. No attempt was made to control for LDASA use in these studies. Adjudication of PE and PTB cases was blinded, occurring prior to database lockdown and analyses.

Discovery was performed in a PAPR-derived cohort that was distinct from the TREETOP-derived verification and validation cohorts (**Fig. 1**). The discovery and verification/validation cohorts included blood samples drawn $18^{0/7}$-$22^{6/7}$ and $18^{0/7}$-$20^{6/7}$ weeks' gestation, respectively. The discovery cohort used a broader GA at blood draw (GABD) window to increase sample size. TREETOP subjects enrolled before April 18, 2018 were randomly assigned by an independent third-party statistician to blinded verification (one-third) or validation (two-thirds) cohorts.[24] The validation cohort also included six months of later enrollment at four additional sites not represented in the verification cohort. Cases were defined as subjects with PE who delivered <37 weeks' gestation, and controls were defined as noncases, inclusive of term PE and sPTB.

Maternal blood was collected, processed and stored as described previously.[23,24] Serum samples were depleted of abundant proteins, reduced, alkylated, and digested with trypsin. Stable isotope standard (SIS) peptides were added post-digest, and peptides were analyzed by a liquid chromatography-multiple reaction monitoring mass spectrometry assay.[23,27] Quantification was based on peptide response ratios, wherein the area of each endogenous peptide was divided by that of its corresponding SIS. Sample batches were required to meet quality control metrics.

Biomarker measurements were made for 77 proteins, comprising those enriched for pathways relevant to pregnancy conditions and quality control proteins. Proteins for building classifier models were prefiltered using analytical performance criteria, including mass spectrometry peak area cutoffs, coefficients of variance from replicate quality control samples, and preanalytic stability. Simple models were then constructed to avoid overfitting and to leverage protein ratios for normalizing and amplifying

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

predictive signals[23]. Models included one novel two-protein ratio and a composite clinical variable. Based on strong predictive performance in nulliparous individuals, the log ratio of insulin-like growth factor-binding protein 4 (IBP4) to sex hormone-binding globulin (SHBG) was included in models as a second two-protein ratio unless SHBG was part of the novel ratio. Among many clinical factors specified in current practice guidelines,[7,28-32] three (PE in a previous pregnancy, pre-existing hypertension, and pregestational diabetes) were selected and combined into one variable (ClinRisk3), which was deemed positive if any was true for the subject. This simple, fixed approach reduced overfitting, leveraged prior biomarker knowledge, and produced classifiers that followed two model structures:

1. A_1*log(IBP4/SHBG) + A_2*ClinRisk3 + A3*log(X/Y) or
2. A_1*ClinRisk3 + A_2*log (X/SHBG)

where X and Y are protein analytes, identified herein by Uniprot name without species identifier. Model coefficients A_i were fit using logistic regression.

In discovery, models were ranked by a combination of area under the receiver operating characteristic curve (AUC) and correlation with GAD amongst preeclamptic subjects. Candidate models ascertained in discovery were confirmed and tuned in verification to account for temporal changes in care and population, then validated by an independent third-party statistician. Each classifier was initially validated using AUC, then *P*-value, for three score thresholds distinguishing higher from lower risk. Thresholds were predefined based on discovery performance to allow for sensitivity and specificity tradeoffs and to enable use in varied clinical settings.

Previously we showed that for prediction of spontaneous PTB using protein biomarkers, better estimation of test performance is obtained in more precisely GA-dated individuals.[33] Since crown-rump length is more precise when determined prior to $9^{0/7}$ weeks' gestation,[26] post-validation performance metrics were calculated on a sub-cohort comprised of subjects dated by ultrasound prior to $9^{0/7}$-weeks' gestation (early GA dating). Performance metrics were calculated for GA cutoffs of <37 and <34 weeks in

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

all subjects and in nulliparous individuals. PE prevalence was calculated on the TREETOP validation cohort and was consistent with the broader U.S. population, as represented by National Vital Statistics System (NVSS) reporting[34] and Lisonkova et al. (2013)[8] (e.g., for PE <34 weeks: TREETOP, 1.13%; Lisonkova, 1.24%; *P*=0.78).

Guidelines[35] set by the U.S. Preventive Services Task Force (USPSTF) for PE clinical risk factor assessment were compared to the biomarker-driven model. The TREETOP validation dataset contained most USPSTF-prescribed clinical risk factors, including prior history of preeclampsia, chronic hypertension, type 1 or type 2 diabetes, kidney disease, multi-gestational birth, elevated pre-pregnancy body mass index, instances of nulliparous births, and maternal African American heritage (attributed to socioeconomic factors). Using these variables, a classifier was developed to approximate the USPSTF risk assessment and compare its performance with biomarker-driven models using the same predefined benchmarks.

Analyses were conducted according to prespecified protocols. Laboratory personnel and statisticians were blinded to clinical data. Data linked to classifier scores were analyzed by an independent third-party statistician. Type I error was controlled by fixed sequence hypothesis testing.[36,37] The sample size of the validation sub-cohort was shown to have 84% power at 5% alpha to detect by Fisher's exact test an enrichment of spontaneous PTB cases above a predictor score threshold associated with two-fold increased risk.[38] For the purpose of validating preterm PE classifiers, this sub-cohort was estimated to show >90% power at 5% alpha to detect by regression test a significant enrichment above a 75% sensitivity threshold. At such a threshold, the sub-cohort sample size was estimated to produce a 95% CI width for sensitivity of <25% and for specificity of <5%.

Unless otherwise specified, all statistical tests were 2-tailed at significance <0.05 and performed in R v3.5.1 or higher.[39] Count differences in categorical variables were assessed using the chi-squared test, and median differences in continuous variables were assessed with the Wilcoxon test.[40]

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Comparison across cohorts was performed using the Kruskal-Wallis test. Overall predictive performance was assessed via AUC with direction of effect prespecified, significance assessed with a 1-sided Wilcoxon test, and confidence intervals (CI) calculated using DeLong's method.[41] Clinical validity was assessed using predictive performance and statistically significant stratification of preterm PE subjects above vs below threshold scores. Following validation, sensitivity, specificity, PPV, NPV, SPR, likelihood ratios (LR+/-), and odds ratios (OR) were calculated for preterm PE (GAD <37 weeks), and early preterm PE (GAD <34 weeks) for the entire validation cohort (all parities) and for nulliparas only. Calculation of prevalence-dependent predictor performance used the prevalence of the analysed outcome in the entire TREETOP-based validation cohort, as well as the early GA dating subset.

Results

Characteristics of the discovery, verification, and validation cohorts are summarized in **Table 1** and **Fig. 1**. Subjects delivering with preterm PE were more likely than controls to have higher BMI, prior PE, chronic hypertension, pregestational diabetes, and longer neonatal hospital stays. GABD showed no significant difference between cases and controls in any cohort.

No significant differences were seen across cohorts for chronic hypertension and pregestational diabetes, but prior PE was increased among validation cohort controls (**Appendix 1**). There were also significant differences between cohorts in race, ethnicity, parity, educational attainment, maternal age, BMI, and GAD. Despite both case/control and cohort differences, regression analysis showed that maternal age and BMI did not contribute independently to preterm PE risk. The significant difference in GABD reflected the broader collection window in the discovery cohort.

Nine of nine classifiers ascertained in discovery showed acceptable predictive performance in verification for risk of preterm PE with GAD <37 weeks. In validation, all nine exhibited significant AUCs (0.72-0.78) for preterm PE risk prediction, significant risk stratification at three threshold scores, and

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

significant Pearson correlations between predictor score and GAD among individuals with PE (**Appendix 2**). ClinRisk3 alone exhibited an AUC of 0.68 for preterm PE, falling below the lower 95% CI of most of the validated combined classifiers. **Fig. 2** shows ROC curves for the predictor with the largest AUC (0.78), ClinRisk3 + inhibin beta c chain/SHBG (ClinRisk3+INHBC/SHBG), in the full validation cohort for (A) all parity and (B) nulliparas.

For prediction of preterm PE <37 weeks' gestation in gravidas with any parity or nulliparas, **Table 2** details ClinRisk3+INHBC/SHBG performance for validation cohort subjects with early GA dating, and **Appendix 3** shows its performance in the full validation cohort. In the early GA dating sub-cohort, setting the ClinRisk3+INHBC/SHBG cutoff to achieve a specificity of at least 90%, the sensitivity for prediction of preterm PE with GAD <37 weeks for all parities was 51.7%, with a SPR 11.1%, PPV 13.0%, NPV 98.5%, and OR 9.93; the performance for nulliparas was extremely similar, with the exception of a lower PPV (6.9%) and higher NPV (99.8%). We also applied USPSTF clinical practice guidelines[35] to our validation cohort – either the entire validation cohort (**Appendix 3**) or the sub-cohort with early GA dating (**Table 2**). In these comparisons, predictive performance for the combination of ClinRisk3 and INHBC/SHBG was superior to that of USPSTF guidelines.

Discussion

Nine classifier models predictive of preterm PE risk were validated, with ClinRisk3+INHBC/SHBG showing the best overall performance. Requiring simplicity (one or two bivariate protein biomarkers and a composite clinical variable) and using large, diverse, and temporally divergent cohorts mitigated overfitting and enabled validation in an independent population. Three clinical features that differed significantly between cases and controls in the discovery cohort (prior PE, pre-existing hypertension, and pregestational diabetes) comprised the composite clinical variable. A fourth, BMI, was excluded as it did not contribute independently to preterm PE risk, perhaps due to strong associations between BMI and

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

both diabetes and SHBG.[42,43] Emphasizing strong predictive performance in both nulliparous and multiparous pregnancies during discovery ensures broad applicability. In the two source cohorts, Black (17.8-19.0%) and Hispanic (37.3-41.2%) subjects were represented at proportions higher than those in the general U.S. birthing population (14.1-15.2% Black; 23.7-24.2% Hispanic),[44,45] ensuring generalizability.

Inhibin and activin, members of the transforming growth factor beta (TGFβ) family, are dysregulated in pregnancy disorders. Elevated maternal serum Inhibin A was first reported as a biomarker of fetal aneuploidy[46] but is also associated with PE,[47,48] including preclinical PE.[49] However, Inhibin A, alone or in combination with other aneuploidy and fetal anomaly biomarkers, demonstrates insufficient predictive performance for clinical use.[50,51] INHBC, a less well-characterized inhibin family member comprised of activin C homodimers, was recently reported to function through activin receptor-like kinase 7 (ALK7), which participates in angiogenesis, cytokine activity, hormone signaling, and embryonic development.[52] Expressed in villous and extravillous trophoblasts, ALK7 is dysregulated in placentas from individuals with PE[53] and is a mediator of hypoxia-induced impairment trophoblast invasion.[54] A potential role for INHBC in extravillous trophoblast development and function may help explain its predictive value for preterm PE (**Fig. 3**).

SHBG regulates biologically active free steroid hormone levels,[55] increases up to 10-fold in the maternal circulation during pregnancy, and is expressed by placental trophoblasts.[55,56] SHBG transcription is suppressed by pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α),[57] which is relevant because inflammation, along with increased placental[58] and circulating[59] TNF-α, is associated with PE (**Fig. 3**). Dysregulation of maternal circulating SHBG in PE has been reported by some[60] and disputed by others[61-65], perhaps due to variability in PE phenotype and GABD among studies. Even in studies associating SHBG with PE, its predictive performance is poor.[60] In non-pregnant adults, low serum SHBG has been associated with insulin resistance,[66] Type 2 diabetes,[67] and endothelial

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

dysfunction.[68] In one study, gravidas with low first-trimester SHBG and PlGF were at highest risk of developing PE, leading authors to conclude that dysregulated angiogenesis and insulin resistance exerted additive effects on PE risk.[66] Similarly, these results suggest that SHBG is an independent PE risk predictor due to potential effects on insulin resistance and endothelial function, and predictive performance improves markedly when combined with an angiogenic factor such as INHBC.

Since the validated ClinRisk3+INHBC/SHBG predictor makes early risk assessment possible for preterm PE (<37 weeks) in a given pregnancy for any parity, it can enable individualized clinical management. Individuals at higher risk can be assigned to increased surveillance (e.g., more frequent antenatal visits, home blood pressure monitoring) for early detection of PE and associated complications, along with nutritional modification, exercise coaching, and other interventions,[69] while those at lower risk can safely avoid unnecessary interventions. Determining whether our predictors will be useful for decision-making regarding LDASA prophylaxis requires more study, to establish LDASA efficacy among patients for whom guideline criteria and the predictors produce discordant risk assessments.

ClinRisk3+INHBC/SHBG provided excellent stratification of subjects at elevated risk for early-onset preterm PE (diagnosis <34 weeks' GA), an outcome with a large clinical burden and unmet need. ACOG recommends delivery for PE diagnosed ≥34 weeks' GA and expectant management with close observation for those diagnosed earlier.[7] Clark et al. (2023)[70] recently recommended changes to classification of different PE subtypes to better reflect the type and degree of associated organ dysfunction. We acknowledge that, if adopted, such recommendations may alter clinical decision-making relevant to timing of delivery for PE. In addition, new prevention or treatment strategies may be developed. Any of these developments may require us to reassess predictor performance in the appropriate contexts.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Clinical practice guidelines include expectations for test performance, including high PPV, to limit overtreatment.[7] However, PPV is impacted by a condition's prevalence. This study validated predictive algorithms for preterm PE, a clinically important yet low-prevalence PE phenotype, in a cohort with a PE rate similar to the overall U.S. prevalence (2.7% preterm PE, 7.7% all PE). This contrasts with a recent RNA biomarker study[71] that interrogated PE at any GA in a high-risk population (PE rate of 13.6%), which reported a sensitivity of 75.0% and a PPV of 32.3%. We chose to establish a threshold at approximately a 10% false positive rate (FPR), as this is a common practice that helps to avoid overtreatment. It is also common to establish a threshold that results in 10% of a population being screen positive. As our 10% thresholds result in approximately an 11-12% SPR, the performance estimates provided here apply generally for both approaches.

Importantly, according to the current standard of care, PE risk is assessed using a range of clinical algorithms. Specifically, in a large Danish mixed parity cohort, National Institute of Health and Care Excellence (NICE) guidelines[28] had a sensitivity of 47%, PPV of 5.4%, and NPV of 99.6% at a SPR of 8.1%, while American College of Obstetrics and Gynecology (ACOG) guidelines[7] had a sensitivity of 60.5%, PPV of 5.6%, and NPV of 99.7% at a SPR of 18.2% for preterm preeclampsia <37 weeks' GA.[72] In our validation cohort, we applied USPSTF clinical practice guidelines, which yielded a sensitivity of 79.3%, PPV of 5.0%, and NPV of 99.0% at a SPR of 43.4% for preterm preeclampsia <37 weeks' GA. The Fetal Medicine Foundation's (FMF) recommended a more involved screening algorithm[73], including maternal risk factors, maternal mean arterial pressure, the uterine artery pulsatility index, and serum PLGF, which has a reported 79.9% sensitivity, 4.4% PPV, and 99.8% NPV at a SPR of 14.7% for all parities, and 79.0% sensitivity, 3.8% PPV, and 99.8% NPV at a SPR of 19.2% for nulliparas, for preterm PE.[74]

Consisting of straightforward measurement of 2 proteins in a single blood sample combined with easily ascertained clinical factors, the performance of ClinRisk3+INHBC/SHBG in the total validation cohort (sensitivity 51.7%, PPV of 13.0%, and NPV of 98.5% at a SPR of 11.1%) and specifically in

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

nulliparas (sensitivity 53.3%, PPV of 6.9%, and NPV of 99.8% at a SPR of 11.7%) is superior to standard-of-care clinical risk assessment approaches endorsed by NICE, ACOG, and USPSTF, and also compares favorably with the more burdensome approach endorsed by the FMF, which is comprised of not only clinical factors and a protein biomarker, but also uterine artery Doppler measurement, which is unfeasible for universal screening. ClinRisk3+INHBC/SHBG and the other predictors validated in this study can be used to select high-risk pregnancies for interventional studies of prophylactic or therapeutic agents. Determining whether preventive or therapeutic interventions alter biomarker levels in maternal serum is also of interest. Clinical application of a screening test is a two-step process: The first step, reported here, is validation of the biomarkers' predictive abilities. The second, demonstrating clinical utility – i.e., improved outcomes, cost effectiveness, and ease of implementation – requires additional work.

Strengths of the study include the large, diverse, and temporally distinct datasets used for discovery, verification, and validation. The composite clinical variable uses readily ascertained factors, and the biomarkers were prefiltered for excellent performance in ambient temperature sample transport conditions. These properties support practicality for clinical use. Limitations include the modest number of early preterm PE cases due to the low prevalence of the condition and a mid-trimester blood draw window ($18^{0/7}$-$22^{6/7}$ weeks' GA) that falls within the guideline-recommended timeframe for LDASA initiation (12-28 week's GA, optimally <16 weeks' GA).[7]

In summary, nine mid-trimester preterm PE risk predictors, designed to assess both proteomic biomarkers and clinical risk factors from 18-20 weeks' gestation, demonstrated predictive ability superior to that of clinical factors alone. ClinRisk3+INHBC/SHBG includes biomarkers with functional relevance to pregnancy. All show promise for detecting risk of PE <34 weeks' GA and identifying pre-symptomatic individuals who can benefit from increased surveillance, LDASA prophylaxis, and future therapies.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

References

1. Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: Pathophysiology, Challenges, and Perspectives. *Circ Res*. Mar 29 2019;124(7):1094-1112. doi:10.1161/CIRCRESAHA.118.313276

2. Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. *Lancet Glob Health*. Jun 2014;2(6):e323-33. doi:10.1016/S2214-109X(14)70227-X

3. Vogel JP, Souza JP, Mori R, Morisaki N, Lumbiganon P, Laopaiboon M, et al. Maternal complications and perinatal mortality: findings of the World Health Organization Multicountry Survey on Maternal and Newborn Health. *BJOG*. Mar 2014;121 Suppl 1:76-88. doi:10.1111/1471-0528.12633

4. Ananth CV, Vintzileos AM. Medically indicated preterm birth: recognizing the importance of the problem. *Clin Perinatol*. Mar 2008;35(1):53-67, viii. doi:10.1016/j.clp.2007.11.001

5. Henderson JT, Vesco KK, Senger CA, Thomas RG, Redmond N. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA*. Sep 28 2021;326(12):1192-1206. doi:10.1001/jama.2021.8551

6. Chronic Hypertension in Pregnancy. ACOG Practice Bulletin No. 203. American College of Obstetricians and Gynecologists. *Obstet Gynecol*. Jan 2019;133(1)e26-e50.doi:10.1097/AOG.0000000000003020

7. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. American College of Obstetricians and Gynecologists. *Obstet Gynecol*. Jun 2020;135(6)e237-e260.doi:10.1097/AOG.0000000000003891

8. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. *Am J Obstet Gynecol*. Dec 2013;209(6):544 e1-544 e12. doi:10.1016/j.ajog.2013.08.019

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

9. Hao J, Hassen D, Hao Q, Graham J, Paglia MJ, Brown J, et al. Maternal and Infant Health Care Costs Related to Preeclampsia. *Obstet Gynecol*. Dec 2019;134(6):1227-1233. doi:10.1097/AOG.0000000000003581

10. Baumann MU, Bersinger NA, Surbek DV. Serum markers for predicting pre-eclampsia. *Mol Aspects Med*. Apr 2007;28(2):227-44. doi:10.1016/j.mam.2007.04.002

11. Bahado-Singh RO, Syngelaki A, Akolekar R, Mandal R, Bjondahl TC, Han B, et al. Validation of metabolomic models for prediction of early-onset preeclampsia. *Am J Obstet Gynecol*. Oct 2015;213(4):530 e1-530 e10. doi:10.1016/j.ajog.2015.06.044

12. Koster MP, Vreeken RJ, Harms AC, Dane AD, Kuc S, Schielen PC, et al. First-Trimester Serum Acylcarnitine Levels to Predict Preeclampsia: A Metabolomics Approach. *Dis Markers*. 2015;2015:857108. doi:10.1155/2015/857108

13. Srinivasan S, Treacy R, Herrero T, Olsen R, Leonardo TR, Zhang X, et al. Discovery and Verification of Extracellular miRNA Biomarkers for Non-invasive Prediction of Pre-eclampsia in Asymptomatic Women. *Cell Rep Med*. May 19 2020;1(2)doi:10.1016/j.xcrm.2020.100013

14. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrom M, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. *N Engl J Med*. Jan 7 2016;374(1):13-22. doi:10.1056/NEJMoa1414838

15. Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, et al. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. *Lancet*. May 4 2019;393(10183):1807-1818. doi:10.1016/S0140-6736(18)33212-4

16. Di Lorenzo G, Ceccarello M, Cecotti V, Ronfani L, Monasta L, Vecchi Brumatti L, et al. First trimester maternal serum PIGF, free β-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

for the prediction of preeclampsia. *Placenta*. Jun 2012;33(6):495-501. doi:10.1016/j.placenta.2012.03.003

17. Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH. Combined screening for preeclampsia and small for gestational age at 11-13 weeks. *Fetal Diagn Ther*. 2013;33(1):16-27. doi:10.1159/000341712

18. Leavey K, Benton SJ, Grynspan D, Kingdom JC, Bainbridge SA, Cox BJ. Unsupervised Placental Gene Expression Profiling Identifies Clinically Relevant Subclasses of Human Preeclampsia. *Hypertension*. Jul 2016;68(1):137-47. doi:10.1161/HYPERTENSIONAHA.116.07293

19. Roberts JM, Rich-Edwards JW, McElrath TF, Garmire L, Myatt L, Global Pregnancy C. Subtypes of Preeclampsia: Recognition and Determining Clinical Usefulness. *Hypertension*. May 5 2021;77(5):1430-1441. doi:10.1161/HYPERTENSIONAHA.120.14781

20. Robillard PY, Dekker G, Scioscia M, Saito S. Progress in the understanding of the pathophysiology of immunologic maladaptation related to early-onset preeclampsia and metabolic syndrome related to late-onset preeclampsia. *Am J Obstet Gynecol*. Feb 2022;226(2S):S867-S875. doi:10.1016/j.ajog.2021.11.019

21. Masini G, Foo LF, Tay J, Wilkinson IB, Valensise H, Gyselaers W, Lees CC. Preeclampsia has two phenotypes which require different treatment strategies. *Am J Obstet Gynecol*. Feb 2022;226(2S):S1006-S1018. doi:10.1016/j.ajog.2020.10.052

22. Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials, Board on Health Care Services, Board on Health Sciences Policy, Institute of Medicine. In: Micheel CM, Nass SJ, Omenn GS, eds. *Evolution of Translational Omics: Lessons Learned and the Path Forward*. National Academies Press (US) Copyright 2012 by the National Academy of Sciences. All rights reserved.; 2012.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

23. Saade GR, Boggess KA, Sullivan SA, Markenson GR, Iams JD, Coonrod DV, et al. Development and validation of a spontaneous preterm delivery predictor in asymptomatic women. *Am J Obstet Gynecol*. May 2016;214(5):633 e1-633 e24. doi:10.1016/j.ajog.2016.02.001

24. Markenson GR, Saade GR, Laurent LC, Heyborne KD, Coonrod DV, Schoen CN, et al. Performance of a proteomic preterm delivery predictor in a large independent prospective cohort. *Am J Obstet Gynecol MFM*. Aug 2020;2(3):100140. doi:10.1016/j.ajogmf.2020.100140

25. American College of Obstetricians and Gynecologists. Committee opinion no 611: method for estimating due date. *Obstet Gynecol*. Oct 2014;124(4):863-866. doi:10.1097/01.AOG.0000454932.15177.be

26. Methods for Estimating the Due Date. Committee Opinion No 700 American College of Obstetricians and Gynecologists. *Obstet Gynecol*. May 2017;129(5)e150-e154.doi:10.1097/AOG.0000000000002046

27. Bradford C, Severinsen R, Pugmire T, Rasmussen M, Stoddard K, Uemura Y, et al. Analytical validation of protein biomarkers for risk of spontaneous preterm birth. *Clinical Mass Spectrometry*. 2017/01/01/ 2017;3:25-38. doi:10.1016/j.clinms.2017.06.002

28. National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management (NICE Guideline, NG 133). Accessed November 22, 2022, https://www.ncbi.nlm.nih.gov/books/NBK546004/

29. Lowe SA, Bowyer L, Lust K, McMahon LP, Morton M, North RA, et al. SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. *Aust N Z J Obstet Gynaecol*. Oct 2015;55(5):e1-29. doi:10.1111/ajo.12399

30. Magee LA, Smith GN, Bloch C, Cote AM, Jain V, Nerenberg K, et al. Guideline No. 426: Hypertensive Disorders of Pregnancy: Diagnosis, Prediction, Prevention, and Management. *J Obstet Gynaecol Can*. May 2022;44(5):547-571 e1. doi:10.1016/j.jogc.2022.03.002

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

31. World Health Organization. *WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia.* Geneva: World Health Organization; 2011.

32. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. *Hypertension*. Jul 2018;72(1):24-43. doi:10.1161/HYPERTENSIONAHA.117.10803

33. Burchard J, Saade GR, Boggess KA, Markenson GR, Iams JD, Coonrod DV, et al. Better Estimation of Spontaneous Preterm Birth Prediction Performance through Improved Gestational Age Dating. *J Clin Med*. May 19 2022;11(10)doi:10.3390/jcm11102885

34. Osterman MJK, Hamilton BE, Martin JA, Driscoll AK, Valenzuela CP. Births: Final Data for 2021. *Natl Vital Stat Rep*. Jan 2023;72(1):1-53.

35. Bibbins-Domingo K, Grossman DC, Curry SJ, Barry MJ, Davidson KW, Doubeni CA, et al. Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement. *Jama*. Apr 25 2017;317(16):1661-1667. doi:10.1001/jama.2017.3439

36. Dmitrienko A, Tamhane A, Bretz F, eds. *Multiple Testing Problems in Pharmaceutical Statistics*. CRC Press; 2009.

37. Dmitrienko A, D'Agostino RB, Sr., Huque MF. Key multiplicity issues in clinical drug development. *Stat Med*. Mar 30 2013;32(7):1079-111. doi:10.1002/sim.5642

38. Burchard J, Polpitiya AD, Fox AC, Randolph TL, Fleischer TC, Dufford MT, et al. Clinical Validation of a Proteomic Biomarker Threshold for Increased Risk of Spontaneous Preterm Birth and Associated Clinical Outcomes: A Replication Study. *J Clin Med*. Oct 29 2021;10(21):5088. doi:10.3390/jcm10215088

39. R Foundation. The R Project for Statistical Computing. Accessed August 1, 2022, https://www.r-project.org/

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

40. Yoshida K, Bartel A. tableone: Create 'Table 1' to Describe Baseline Characteristics with or without Propensity Score Weights; R package version 0.13.2. Accessed November 21, 2022, https://cran.r-project.org/web/packages/tableone/index.html

41. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics*. Sep 1988;44(3):837-45.

42. Cooper LA, Page ST, Amory JK, Anawalt BD, Matsumoto AM. The association of obesity with sex hormone-binding globulin is stronger than the association with ageing--implications for the interpretation of total testosterone measurements. *Clin Endocrinol (Oxf)*. Dec 2015;83(6):828-33. doi:10.1111/cen.12768

43. Birkebaek NH, Lange A, Holland-Fischer P, Kristensen K, Rittig S, Vilstrup H, et al. Effect of weight reduction on insulin sensitivity, sex hormone-binding globulin, sex hormones and gonadotrophins in obese children. *Eur J Endocrinol*. Dec 2010;163(6):895-900. doi:10.1530/EJE-10-0538

44. Osterman MJK, Hamilton BE, Martin, J.A., Driscoll AKV, C.P. Births: Final Data for 2020. Division of Vital Statistics, National Center for Health Statistics, U.S. Centers for Disease Control and Prevention. Updated 2022 Feb 7. Accessed February 9, 2022, https://www.cdc.gov/nchs/nvss/births.htm

45. March of Dimes Peristats. Births. Accessed July 1, 2023, https://www.marchofdimes.org/peristats/data?reg=99&top=2&stop=10&lev=1&slev=1&obj=3

46. Aitken DA, Wallace EM, Crossley JA, Swanston IA, van Pareren Y, van Maarle M, et al. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. *N Engl J Med*. May 9 1996;334(19):1231-6. doi:10.1056/NEJM199605093341904

47. Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL. Activin A and inhibin A as possible endocrine markers for pre-eclampsia. *Lancet*. May 3 1997;349(9061):1285-8. doi:10.1016/s0140-6736(96)09264-1

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

48. Fraser RF, 2nd, McAsey ME, Coney P. Inhibin-A and pro-alpha C are elevated in preeclamptic pregnancy and correlate with human chorionic gonadotropin. *Am J Reprod Immunol*. Jul 1998;40(1):37-42. doi:10.1111/j.1600-0897.1998.tb00386.x

49. Muttukrishna S, North RA, Morris J, Schellenberg JC, Taylor RS, Asselin J, et al. Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia. *Hum Reprod*. Jul 2000;15(7):1640-5. doi:10.1093/humrep/15.7.1640

50. Morris RK, Cnossen JS, Langejans M, Robson SC, Kleijnen J, Ter Riet G, et al. Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. *BMC Pregnancy Childbirth*. Aug 4 2008;8:33. doi:10.1186/1471-2393-8-33

51. Huang T, Bedford HM, Rashid S, Rasasakaram E, Priston M, Mak-Tam E, et al. Modified multiple marker aneuploidy screening as a primary screening test for preeclampsia. *BMC Pregnancy Childbirth*. Mar 8 2022;22(1):190. doi:10.1186/s12884-022-04514-4

52. Goebel EJ, Ongaro L, Kappes EC, Vestal K, Belcheva E, Castonguay R, et al. The orphan ligand, activin C, signals through activin receptor-like kinase 7. *Elife*. Jun 23 2022;11doi:10.7554/eLife.78197

53. Nadeem L, Munir S, Fu G, Dunk C, Baczyk D, Caniggia I, et al. Nodal signals through activin receptor-like kinase 7 to inhibit trophoblast migration and invasion: implication in the pathogenesis of preeclampsia. *Am J Pathol*. Mar 2011;178(3):1177-89. doi:10.1016/j.ajpath.2010.11.066

54. Hu M, Wang Y, Meng Y, Hu J, Qiao J, Zhen J, et al. Hypoxia induced-disruption of lncRNA TUG1/PRC2 interaction impairs human trophoblast invasion through epigenetically activating Nodal/ALK7 signalling. *J Cell Mol Med*. Jul 2022;26(14):4087-4100. doi:10.1111/jcmm.17450

55. Hammond GL. Diverse roles for sex hormone-binding globulin in reproduction. *Biol Reprod*. Sep 2011;85(3):431-41. doi:10.1095/biolreprod.111.092593

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

56. Larrea F, Diaz L, Carino C, Larriva-Sahd J, Carrillo L, Orozco H, Ulloa-Aguirre A. Evidence that human placenta is a site of sex hormone-binding globulin gene expression. *J Steroid Biochem Mol Biol*. Oct 1993;46(4):497-505. doi:10.1016/0960-0760(93)90104-5

57. Simo R, Saez-Lopez C, Barbosa-Desongles A, Hernandez C, Selva DM. Novel insights in SHBG regulation and clinical implications. *Trends Endocrinol Metab*. Jul 2015;26(7):376-83. doi:10.1016/j.tem.2015.05.001

58. Rinehart BK, Terrone DA, Lagoo-Deenadayalan S, Barber WH, Hale EA, Martin JN, Jr., Bennett WA. Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia. *Am J Obstet Gynecol*. Oct 1999;181(4):915-20. doi:10.1016/s0002-9378(99)70325-x

59. Conrad KP, Miles TM, Benyo DF. Circulating levels of immunoreactive cytokines in women with preeclampsia. *Am J Reprod Immunol*. Aug 1998;40(2):102-11. doi:10.1111/j.1600-0897.1998.tb00398.x

60. Yu CK, Papageorghiou AT, Bindra R, Spencer K, Nicolaides KH. Second-trimester sex hormone-binding globulin and subsequent development of pre-eclampsia. *J Matern Fetal Neonatal Med*. Sep 2004;16(3):158-62. doi:10.1080/14767050400013297

61. Nevalainen J, Korpimaki T, Kouru H, Sairanen M, Ryynanen M. Performance of first trimester biochemical markers and mean arterial pressure in prediction of early-onset pre-eclampsia. *Metabolism*. Oct 2017;75:6-15. doi:10.1016/j.metabol.2017.07.004

62. Sharifzadeh F, Kashanian M, Fatemi F. A comparison of serum androgens in pre-eclamptic and normotensive pregnant women during the third trimester of pregnancy. *Gynecol Endocrinol*. Oct 2012;28(10):834-6. doi:10.3109/09513590.2012.683061

63. Tuutti EK, Hamalainen EK, Sainio SM, Hiilesmaa VK, Turpeinen UL, Alfthan HV, Stenman UH. Serum testosterone levels during early pregnancy in patients developing preeclampsia. *Scand J Clin Lab Invest*. Sep 2011;71(5):413-8. doi:10.3109/00365513.2011.580858

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

64. Sun L, Jin Z, Teng W, Chi X, Zhang Y, Ai W, Wang P. Expression changes of sex hormone binding globulin in GDM placental tissues. *J Perinat Med*. Nov 19 2011;40(2):129-35. doi:10.1515/JPM.2011.128

65. Anderson DC. Sex-hormone-binding globulin. *Clin Endocrinol (Oxf)*. Jan 1974;3(1):69-96. doi:10.1111/j.1365-2265.1974.tb03298.x

66. Thadhani R, Ecker JL, Mutter WP, Wolf M, Smirnakis KV, Sukhatme VP, et al. Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. *Hypertension*. May 2004;43(5):988-92. doi:10.1161/01.HYP.0000124460.67539.1d

67. Wallace IR, McKinley MC, Bell PM, Hunter SJ. Sex hormone binding globulin and insulin resistance. *Clin Endocrinol (Oxf)*. Mar 2013;78(3):321-9. doi:10.1111/cen.12086

68. Maggio M, Cattabiani C, Lauretani F, Mantovani M, Butto V, De Vita F, et al. SHBG and endothelial function in older subjects. *Int J Cardiol*. Oct 3 2013;168(3):2825-30. doi:10.1016/j.ijcard.2013.03.083

69. Roberts JM, King TL, Barton JR, Beck S, Bernstein IM, Buck TE, et al. Care plan for individuals at risk for preeclampsia: shared approach to education, strategies for prevention, surveillance, and follow-up. *Am J Obstet Gynecol*. Sep 2023;229(3):193-213. doi:10.1016/j.ajog.2023.04.023

70. Clark SL, Saade GA, Tolcher MC, Belfort MA, Rouse DJ, Barton JR, et al. Gestational hypertension and "severe" disease: time for a change. *Am J Obstet Gynecol*. May 2023;228(5):547-552. doi:10.1016/j.ajog.2022.11.1280

71. Rasmussen M, Reddy M, Nolan R, Camunas-Soler J, Khodursky A, Scheller NM, et al. RNA profiles reveal signatures of future health and disease in pregnancy. *Nature*. Jan 2022;601(7893):422-427. doi:10.1038/s41586-021-04249-w

72. Rode L, Ekelund CK, Riishede I, Rasmussen S, Lidegaard O, Tabor A. Prediction of preterm pre-eclampsia according to NICE and ACOG criteria: descriptive study of 597 492 Danish births from 2008 to 2017. *Ultrasound Obstet Gynecol*. Oct 2021;58(4):561-567. doi:10.1002/uog.23693

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

73. Chaemsaithong P, Sahota DS, Poon LC. First trimester preeclampsia screening and prediction. *Am J Obstet Gynecol*. Feb 2022;226(2S):S1071-S1097 e2. doi:10.1016/j.ajog.2020.07.020

74. Tan MY, Syngelaki A, Poon LC, Rolnik DL, O'Gorman N, Delgado JL, et al. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. *Ultrasound Obstet Gynecol*. Aug 2018;52(2):186-195. doi:10.1002/uog.19112

Table 1. Demographic and clinical characteristics of preterm preeclampsia (PE) cases and noncases in the discovery, verification, and validation cohorts.

	Discovery (PAPR)			Verification (TREETOP)			Validation (TREETOP)		
Cases and noncases	**Preterm PE <37 weeks' gestation**	**No PE or PE ≥37 weeks' gestation**	***P* value**	**Preterm PE <37 weeks' gestation**	**No PE or PE ≥37 weeks' gestation**	***P* value**	**Preterm PE <37 weeks' gestation**	**No PE or PE ≥37 weeks' gestation**	***P* value**
Number of subjects (n, %)	45 (3.3)	1307 (96.7)		34 (2.7)	1217 (97.3)		62 (2.7)	2227 (97.3)	
Maternal age (y)			0.586			0.640			0.705
Median	26	27		28.5	30		30	29	
IQR	24–31	23–32		27–32	25–33		25–34	25–33	
Unknown (n)	0	0		0	0		0	0	
BMI			0.003			0.027			<0.001
Median	29.6	26.6		28.3	26.1		30.9	25.8	
IQR	26.17–38.0	22.7–32.4		25.7–32.9	22.6–31.0		25.9–35.5	22.3–31.1	
Unknown (n)	1	23		1	14		1	25	
Maternal race (n, %)			0.114			0.838			0.579
Black	13 (28.9)	224 (17.1)		5 (14.7)	233 (19.1)		14 (22.6)	393 (17.6)	
White	29 (64.4)	952 (72.8)		21 (61.8)	757 (62.2)		34 (54.8)	1411 (63.4)	
None of the above	3 (6.7)	131 (10.0)		7 (20.6)	205 (16.8)		12 (19.4)	370 (16.6)	
Unknown (n)	0 (0.0)	0 (0.0)		1 (2.9)	22 (1.8)		2 (3.2)	53 (2.4)	
Maternal ethnicity (n, %)			0.180			0.104			0.243
Hispanic	12 (26.7)	492 (37.6)		20 (58.8)	495 (40.7)		30 (48.4)	895 (40.2)	
Non-Hispanic	33 (73.3)	815 (62.4)		14 (41.2)	720 (59.2)		32 (51.6)	1332 (59.8)	
Unknown (n)	0 (0.0)	0 (0.0)		0 (0.0)	2 (0.2)		0 (0.0)	0 (0.0)	
Maternal education level (n, %)			0.131			0.329			0.194
No high school graduation	17 (37.8)	338 (25.9)		4 (11.8)	192 (15.8)		10 (16.1)	317 (14.2)	
High school degree/GED	21 (46.7)	635 (48.6)		21 (61.8)	558 (45.9)		35 (56.5)	1033 (46.4)	
College degree	6 (13.3)	323 (24.7)		9 (26.5)	463 (38.0)		16 (25.8)	861 (38.7)	
Unknown (n)	1 (2.2)	11 (0.8)		0 (0.0)	4 (0.3)		1 (1.6)	16 (0.7)	
Parity (n, %)			0.591			0.838			0.307
Nulliparous (*P*=0)	18 (40.0)	457 (35.0)		13 (38.2)	505 (41.5)		31 (50.0)	950 (42.7)	
Multiparous (*P*≥1)	27 (60.0)	850 (65.0)		21 (61.8)	712 (58.5)		31 (50.0)	1277 (57.3)	
Unknown	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
Previous PE (preterm + term) (n, %)			<0.001			<0.001			<0.001
No	13 (48.1)	777 (91.4)		11 (52.4)	653 (91.7)		18 (58.1)	1102 (86.3)	
Yes	14 (51.9)	73 (8.6)		10 (47.6)	59 (8.3)		13 (41.9)	175 (13.7)	
Unknown	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
Chronic hypertension (n, %)			<0.001			<0.001			<0.001
No	35 (77.8)	1229 (94.0)		26 (76.5)	1154 (94.8)		37 (59.7)	2124 (95.4)	
Yes	10 (22.2)	78 (6.0)		8 (23.5)	63 (5.2)		25 (40.3)	103 (4.6)	
Unknown (n)	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
Pregestational diabetes mellitus (n, %)			<0.001			0.001			<0.001

	No	31 (68.9)	1250 (95.6)		28 (82.4)	1166 (95.8)		47 (75.8)	2118 (95.1)	
	Yes	14 (31.1)	57 (4.4)		6 (17.6)	51 (4.2)		15 (24.2)	109 (4.9)	
	Unknown (n)	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
Gestational age at blood draw (d)				0.233			0.854			0.600
	Median	137	140		137	136		136.5	137	
	IQR	133–143	132–148		134–140	132–141		130–141	133–141	
	Unknown (n)	0	0		0	0		0	0	
Gestational age at delivery (d)				<0.001			<0.001			<0.001
	Median	248	274		243.5	275		240	275	
	IQR	236–254	267–279		224–253	269–281		226–252	270–280	
	Unknown (n)	0	0		0	0		0	0	
Neonatal length of hospital stay (d)				<0.001			<0.001			<0.001
	Median	5	3		13.5	2		11	2	
	IQR	3-13	2-3		6-28	2-3		4-28	2-3	
	Unknown (n)	0	12		0	6		2	7	
Neonatal gender (n, %)				0.920			0.809			0.676
	Female	23 (51.1)	643 (49.2)		15 (44.1)	603 (49.5)		34 (54.8)	1100 (49.4)	
	Male	22 (48.9)	664 (50.8)		19 (55.9)	613 (50.4)		28 (45.2)	1124 (50.5)	
	Ambiguous	0 (0.0)	0 (0.0)		0 (0.0)	1 (0.1)		0 (0.0)	3 (0.1)	
	Unknown	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		0 (0.0)	3 (0.1)	

Categorical variables are shown with counts and percentages, and continuous variables are shown with medians and interquartile ranges. Comparisons between cases (PE <37 weeks' gestation) and noncases (no PE or PE ≥37 weeks' gestation) were performed using Wilcoxon or chi squared tests as appropriate. Collection of neonatal hospital stay was capped at 28 days according to the PAPR[23] and TREETOP[24] study protocols. BMI, body mass index; IQR, interquartile range; GED, general education diploma; NA, not applicable; PE, preeclampsia; PTB, preterm birth.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Table 2. Predictive performance of ClinRisk3+INHBC/SHBG and a U.S. Preventive Services Task Force clinical risk factor-based classifier (representing standard care) for risk of preeclampsia with delivery <37 weeks' gestation in the early gestational age dating-restricted population.

Tested population	PE <37 weeks' GA cases/ total subjects (%)	Predictor	AUC (95% CI)	Sensitivity	Specificity	SPR	PPV	NPV	LR+	LR-	OR
Early GA dating All parity	29/912 (3.2%)	ClinRisk3 + INHBC/SHBG	0.82 (0.75 – 0.89)	51.7%	90.3%	11.1%	13.0%	98.5%	5.31	0.53	9.93
		USPSTF guidelines (standard of care)	0.69 (0.61 – 0.76)	79.3%	57.8%	43.4%	5.0%	99.0%	1.88	0.36	5.24
Early GA dating Nulliparas	15/376 (4.0%)	ClinRisk3 + INHBC/SHBG	0.81 (0.71 – 0.92)	53.3%	90.0%	11.7%	6.9%	99.8%	5.35	0.52	10.32
		USPSTF guidelines (standard of care)	0.70 (0.61 – 0.80)	86.7%	54.3%	47.3%	2.6%	99.1%	1.90	0.25	7.72

AUC, area under the receiver operating characteristic curve; CI, confidence interval; ClinRisk3, composite clinical risk variable including preeclampsia in a previous pregnancy, pregestational hypertension, and pregestational diabetes; GA, gestational age; INHBC, inhibin subunit beta C chain; NPV, negative predictive value; LR+/-, positive and negative likelihood ratios; OR, odds ratio; PPV, positive predictive value; SHBG, sex hormone-binding globulin; SPR, screen positive rate; USPSTF, U.S. Preventive Services Task Force.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Figure Legends

Fig. 1. Distribution of subjects in the discovery, verification, and validation cohorts.



GA, gestational age.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Fig. 2. Receiver operating characteristic performance for the preterm preeclampsia (PE) classifier ClinRisk3+INHBC/SHBG in the full validation cohort. The plots graph sensitivity (true positive rate) vs 1-specificity (false positive rate) for preterm PE cases with gestational age at delivery <37 and <34 weeks among (A) all subjects and (B) nulliparous subjects only.



AUC, area under the receiver operating characteristic curve; CI, confidence interval; ClinRisk3, composite clinical variable including preeclampsia in a previous pregnancy, pregestational hypertension, and pregestational diabetes; INHBC, inhibin subunit beta c; SHBG, sex hormone binding globulin.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Fig. 3. Potential roles of INHBC and SHBG in placentation. (A) Activin C, a homodimer of INHBC, signals through the ALK7 receptor, which is itself dysregulated in preeclampsia. (B) SHBG expression has been demonstrated to be downregulated by pro-inflammatory cytokines in hepatocytes, and its extra-hepatic expression has been shown to include trophoblasts. (C) A model illustrating the association of INHBC, ALK7 and SHBG with abnormal placentation and aberrant spiral artery remodeling.



ActC, activin C, an INHBC homodimer; ACTRII, activin receptor type 2A; ALK7, activin A receptor type 1C; AMPK, AMP-activated protein kinase; c-Jun, Jun proto-oncogene, AP-1 transcription factor subunit; HNF-4α, hepatocyte nuclear factor 4 alpha; IκBα, NFκB inhibitor alpha; IL1β, interleukin 1 beta; IL1β, interleukin 1 beta receptor; INHBC, inhibin subunit beta c; JNK, mitogen-activated protein kinase 8; MEK1/2, mitogen-activated protein kinase kinases 1 and 2; MMP2/9, matrix metalloproteinases 2 and 9; NFκB, nuclear factor kappa B; SHBG, sex hormone binding globulin; SMAD2/3, SMAD family members 2 and 3; TIMP-1, TIMP metallopeptidase inhibitor 1; TNFα, tumor necrosis factor alpha; TNFRα, tumor necrosis factor alpha receptor.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Supplemental Digital Content

Appendix 1. Comparison of demographic and clinical characteristics across the discovery, verification, and validation cohorts.

		Discovery (PAPR)	Verification (TREETOP)	Validation (TREETOP)	*P* value
Number of subjects		1352	1251	2289	
Maternal age					<0.001
	Median	27	30	29	
	IQR	23–32	25–33	25–33	
	Unknown (n)	0	0	0	
BMI					0.005
	Median	26.6	26.3	26.0	
	IQR	22.7–32.6	22.6–31.0	22.3–31.2	
	Unknown (n)	24	15	26	
Maternal race (n, %)					<0.001
	Black	237 (17.5)	238 (19.0)	407 (17.8)	
	White	981 (72.6)	778 (62.2)	1445 (63.1)	
	None of the above	134 (9.9)	212 (16.9)	382 (16.7)	
	Unknown (n)	0 (0.0)	23 (1.8)	55 (2.4)	
Maternal ethnicity (n, %)					0.028
	Hispanic	504 (37.3)	515 (41.2)	925 (40.4)	
	Non-Hispanic	848 (62.7)	734 (58.7)	1364 (59.6)	
	Unknown (n)	0 (0.0)	2 (0.2)	0 (0.0)	
Maternal education level (n, %)					<0.001
	No high school graduation	355 (26.3)	196 (15.7)	327 (14.3)	
	High school degree/GED	656 (48.5)	579 (46.3)	1068 (46.7)	
	College degree	329 (24.3)	472 (37.7)	877 (38.3)	
	Unknown (n)	12 (0.9)	4 (0.3)	17 (0.7)	
Parity (n, %)					<0.001
	Nulliparous (*P*=0)	475 (35.1)	518 (41.4)	981 (42.9)	
	Multiparous (*P*≥1)	877 (64.9)	733 (58.6)	1308 (57.1)	
	Unknown	0 (0.0)	0 (0.0)	0 (0.0)	
Previous PE (preterm + term) (n, %)					<0.001
	No	790 (90.1)	664 (90.6)	1120 (85.6)	
	Yes	87 (9.9)	69 (9.4)	188 (14.4)	
	Unknown	0 (0.0)	0 (0.0)	0 (0.0)	
Chronic hypertension (n, %)					0.495
	No	1264 (93.5)	1180 (94.3)	2161 (94.4)	
	Yes	88 (6.5)	71 (5.7)	128 (5.6)	
	Unknown (n)	0 (0.0)	0 (0.0)	0 (0.0)	
Pregestational diabetes mellitus (n, %)					0.531
	No	1281 (94.7)	1194 (95.4)	2165 (94.6)	
	Yes	71 (5.3)	57 (4.6)	124 (5.4)	
	Unknown (n)	0 (0.0)	0 (0.0)	0 (0.0)	
Gestational age at blood draw (d)					<0.001
	Median	140	136	137	
	IQR	132–147	132–141	133–141	
	Unknown (n)	0 (0.0)	0 (0.0)	0 (0.0)	
Gestational age at delivery (d)					<0.001
	Median	273	275	274	
	IQR	266–278	268–281	269–280	
	Unknown (n)	0 (0.0)	0 (0.0)	0 (0.0)	
Neonatal length of hospital stay (d)					<0.001
	Median	3	2	2	
	IQR	2–3	2–3	2–3	
	Unknown (n)	12	6	9	
Neonatal gender (n, %)					0.384
	Female	666 (49.3)	618 (49.4)	1134 (49.5)	

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

	Male	686 (50.7)	632 (50.5)	1152 (50.3)	
	Ambiguous	0 (0.0)	1 (0.1)	0 (0.0)	
	Unknown	0 (0.0)	0 (0.0)	3 (0.1)	

Categorical variables are shown with counts and percentages, and continuous variables are shown with medians and interquartile ranges. Comparison among the three cohorts was performed using Kruskal-Wallis or chi squared tests as appropriate. Collection of neonatal hospital stay was capped at 28 days according to the PAPR[23] and TREETOP[24] study protocols.

BMI, body mass index; IQR, interquartile range; GED, general education diploma; NA, not applicable; PE, preeclampsia; PTB, preterm birth.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Appendix 2. Validation performance of nine candidate preeclampsia classifier models. Score thresholds are specific to each classifier and differentiate subjects predicted to be at higher risk for preterm preeclampsia, defined as preeclampsia <37 weeks' gestation, from those predicted to be at lower risk. Three score thresholds distinguishing higher from lower risk were validated for each classifier. The linear relationship between the gestational age at delivery and classifier prediction was assessed by the Pearson correlation coefficient. Validation performance is reported across the nine classifiers without protein specific batch calibration.

Classifier	AUC [95% CI]	1° threshold *P* value	2° threshold *P* value	3° threshold *P* value	Pearson correlation coefficient *r*	Pearson correlation coefficient *P* value
ClinRisk3 + INHBC/SHBG	0.78 [0.73-0.84]	7.26×10^{-13}	2.69×10^{-12}	3.64×10^{-11}	-0.275	2.20×10^{-04}
ClinRisk3 + IBP4/SHBG + AFAM/PRG2	0.77 [0.71-0.83]	4.13×10^{-12}	1.30×10^{-11}	2.26×10^{-11}	-0.29	1.19×10^{-04}
ClinRisk3 + AFAM/SHBG	0.76 [0.69-0.82]	7.36×10^{-11}	7.46×10^{-11}	4.22×10^{-13}	-0.24	1.25×10^{-03}
ClinRisk3 + CD14/SHBG	0.76 [0.70-0.82]	5.27×10^{-12}	1.24×10^{-10}	3.03×10^{-10}	-0.26	4.44×10^{-04}
ClinRisk3 + IBP4/SHBG + AFAM/CSH†	0.76 [0.69-0.82]	6.04×10^{-12}	4.61×10^{-11}	4.22×10^{-11}	-0.25	9.17×10^{-04}
ClinRisk3 + IBP4/SHBG + CD14/PRG2	0.76 [0.70-0.83]	4.61×10^{-11}	2.47×10^{-13}	1.25×10^{-11}	-0.29	7.53×10^{-05}
ClinRisk3 + IBP4/SHBG + PEDF/CSH†	0.76 [0.70-0.82]	1.89×10^{-11}	1.63×10^{-11}	1.51×10^{-11}	-0.26	4.32×10^{-04}
ClinRisk3 + IBP4/SHBG + PEDF/CBPN	0.73 [0.67-0.80]	1.20×10^{-11}	2.00×10^{-11}	4.22×10^{-10}	-0.24	1.16×10^{-03}
ClinRisk3 + IBP4/SHBG + CD14/CBPN	0.72 [0.66-0.79]	1.60×10^{-10}	3.08×10^{-11}	1.28×10^{-10}	-0.25	9.96×10^{-04}

†Represents CSH1 and CSH2. The two proteins differ by one amino acid residue, which is not included in the peptide fragment measured by the predictor.

AFAM, afamin; AUC, area under the receiver operating characteristic curve; CBPN, carboxypeptidase N catalytic chain; CD14, monocyte differentiation antigen CD14; CI, confidence interval; ClinRisk3, composite clinical variable including preeclampsia in a previous pregnancy, pregestational hypertension, and pregestational diabetes; CSH, chorionic somatomammotropin hormone 1/2; IBP4, insulin-like growth factor-binding protein 4; PEDF, pigment epithelium-derived factor; PRG2, bone marrow proteoglycan; SHBG, sex hormone-binding globulin.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.21.22282936; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Appendix 3. Predictive performance of the ClinRisk3+INHBC/SHBG classifier model and a U.S. Preventive Services Task Force[35] clinical risk factor-based classifier (representing standard care) for preterm preeclampsia risk in the full validation cohort.

Cohort	Tested population	Preterm preeclampsia GA (weeks)	Cases/Total Subjects (%)	Predictor	AUC (95% CI)
Full validation cohort	All parity	<37	62/2261 (2.7%)	ClinRisk3+INHBC/SHBG	0.79 (0.74 – 0.85)
				USPSTF guidelines (standard of care)	0.68 (0.63 – 0.73)
		<34	26/2261 (1.1%)	ClinRisk3+INHBC/SHBG	0.83 (0.78 – 0.89)
	Nulliparas	<37	31/969 (3.1%)	ClinRisk3+INHBC/SHBG	0.76 (0.68 – 0.85)
				USPSTF guidelines (standard of care)	0.68 (0.61-0.75)
		<34	13/969 (1.3%)	ClinRisk3+INHBC/SHBG	0.81 (0.73 – 0.90)

AUC, area under the receiver operating characteristic curve; CI, confidence interval; ClinRisk3, composite clinical variable including preeclampsia in a previous pregnancy, pregestational hypertension, and pregestational diabetes; GA, gestational age; INHBC, inhibin subunit beta C chain; SHBG, sex hormone-binding globulin.